THE HEALTH EQUITY STRATEGIES GROUP, LLC

Lobbying for TRAVERE THERAPEUTICS · Pharmaceutical company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · California · House · $16,000.00 income · posted Nov 20, 2025

Lobbying activity 4

Health Issues

Rare kidney disease

Medical/Disease Research/Clinical Labs

Rare kidney disease

Medicare/Medicaid

Rare kidney disease

Pharmacy

Rare kidney disease

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.